Drug Profile
Research programme: small molecule therapeutics - Incozen/Rhizen
Alternative Names: RP 3120; RP 3163; RP 5090; RP 6557; RP-6503Latest Information Update: 28 Nov 2020
Price :
$50
*
At a glance
- Originator Incozen Therapeutics
- Developer Incozen Therapeutics; Rhizen Pharmaceuticals
- Class Small molecules
- Mechanism of Action Calcium channel antagonists; Immunomodulators; Phosphatidylinositol 3 kinase delta inhibitors; Phosphatidylinositol 3 kinase gamma inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Hypersensitivity; Immunological disorders; Lung disorders; Lupus vulgaris; Multiple sclerosis; Rheumatoid arthritis
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for preclinical development in Immunological-disorders in Switzerland (PO)
- 28 Oct 2018 No recent reports of development identified for preclinical development in Lung-disorders in Switzerland (PO)
- 20 Oct 2016 Preclinical development is ongoing for Lung disorders in Switzerland (Rhizen Pharmaceuticals pipeline, October 2016)